huberman glp-1 New Lab podcast out now: THE SCIENCE OF HUNGER & MEDICATIONS TO COMBAT OBESITY with Dr Zachary Knight of @ucsfmedicine Apexmd

Nonsignificant changes in HDL-C levels (-0.04 to 0.00 mmol/L) were reported following liraglutide treatment [66]

This information may help provide context for provider conversations about which formulation and dose strategy could align with an individual's genetic profile, though genetic variants do not predict exact medication response

PMID: 37931265

Other than the gastrointestinal side effects [11], tirzepatide may rarely contribute to sinus tachycardia, acute kidney injury secondary to dehydration, pancreatitis, cholelithiasis, and cholecystitis

Follicle-stimulating hormone (FSH) blood test

For instance, 3.3 billion mg of semaglutide per year would be required for 25% of obese US adults to take 2.4 mg q1wk